Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06256484 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma
A Phase 1 study, sponsored by Atara Biotherapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT06256484: Clinical Trial Phase 1 study, sponsored by Atara Biotherapeutics.
NCT06256484 is a Phase 1 study that was terminated before completion, run by Atara Biotherapeutics. The registered enrollment target is 1 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06256484, a Phase 1 study, was terminated before completion, sponsored by Atara Biotherapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).
Interventions
- DRUG ATA3219
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2024-09-06 |
| Est. Completion | 2025-03-30 |
| Phase | Phase 1 |
Why NCT06256484 stopped before completion
NCT06256484 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 1 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 1 intervention - of which ATA3219 is the first listed.
NCT06256484 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT06256484 about?
NCT06256484 is a clinical study titled "A Study to Evaluate the Safety and Preliminary Efficacy of ATA3219 in Participants With Relapsed/Refractory B-cell Non-Hodgkin Lymphoma". The purpose of this study is to evaluate the safety and preliminary efficacy of ATA3219 in participants with relapsed/refractory (R/R) B-cell non-Hodgkin Lymphoma (NHL).
What is the current status of trial NCT06256484?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2024-09-06. Estimated completion is 2025-03-30.
What interventions are being tested in trial NCT06256484?
The interventions under investigation include: ATA3219 (DRUG).
Who is sponsoring clinical trial NCT06256484?
This trial is sponsored by Atara Biotherapeutics, which has 5 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT06256484's enrollment target sits among peer trials
1 2001st of 2000 the lowest of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI